Aaron Lazorwitz, MD, PhD
he/him/his
Assistant Professor of Obstetrics, Gynecology and Reproductive Sciences; Associate Program Director for Complex Family Planning Fellowship, Obstetrics, Gynecology & Reproductive Sciences
Research & Publications
Biography
Research Summary
Dr. Lazorwitz's primary research interest is focused on the pharmacogenomics of contraception, which is understanding how genetic differences can affect how birth control works. Individuals have widely variable experiences with birth control and differences in our DNA could help explain why birth control is not as effective for some individuals while others experience severe side effects with birth control. Understanding these genetic differences could help lead to personalized medicine tools that allow healthcare providers to prescribe contraception in a more individualized fashion that ideally reduces undesired side effects and maximizes the prevention of unwanted pregnancies.
Research Interests
Pharmacology; Pharmacogenomic Variants; Hormonal Contraception
Selected Publications
- Feasibility and Utility of Posttraumatic Stress Disorder Screening Among Postpartum Patients at an Urban Safety-Net InstitutionDrake E, Larrea N, Wolverton E, Tibbits B, Lazorwitz A, Schultz C. Feasibility and Utility of Posttraumatic Stress Disorder Screening Among Postpartum Patients at an Urban Safety-Net Institution. Obstetrics And Gynecology 2023, 142: 1455-1458. PMID: 37884025, DOI: 10.1097/aog.0000000000005422.
- An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant usersDiamond B, Sheeder J, Lazorwitz A. An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users. Contraception 2023, 129: 110298. PMID: 37802462, PMCID: PMC10842501, DOI: 10.1016/j.contraception.2023.110298.
- Validation of 24-hour trough concentration as a proxy for intensive pharmacokinetic measurements for a combined oral contraceptive pill containing desogestrelLazorwitz A, Sheeder J. Validation of 24-hour trough concentration as a proxy for intensive pharmacokinetic measurements for a combined oral contraceptive pill containing desogestrel. Contraception 2023, 126: 110093. PMID: 37331464, PMCID: PMC10528283, DOI: 10.1016/j.contraception.2023.110093.
- The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic studyLazorwitz A, Sheeder J, Teal S. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study. Contraception 2023, 123: 110035. PMID: 36997081, PMCID: PMC10461170, DOI: 10.1016/j.contraception.2023.110035.
- Herbal supplement use among reproductive-aged women in an academic infertility practiceFriedman J, Sheeder J, Lazorwitz A, Polotsky A. Herbal supplement use among reproductive-aged women in an academic infertility practice. F&S Reports 2022, 4: 104-111. PMID: 36959959, PMCID: PMC10028423, DOI: 10.1016/j.xfre.2022.12.001.
- P077Pilot study on a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implantClure C, Sheeder J, Lazorwitz A. P077Pilot study on a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant. Contraception 2022, 116: 91. DOI: 10.1016/j.contraception.2022.09.101.
- P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducerLazorwitz A, Teal S, Sheeder J. P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer. Contraception 2022, 116: 92. DOI: 10.1016/j.contraception.2022.09.103.
- Short-notice cancellations of laparoscopic permanent contraceptionMasten M, Larrea N, Schultz C, Lazorwitz A. Short-notice cancellations of laparoscopic permanent contraception. Contraception 2022, 114: 49-53. PMID: 35545130, DOI: 10.1016/j.contraception.2022.04.013.
- Herbal Supplement Use Among Adolescent Women in a Family Planning ClinicFriedman J, Sheeder J, Lazorwitz A. Herbal Supplement Use Among Adolescent Women in a Family Planning Clinic. Journal Of Pediatric And Adolescent Gynecology 2022, 35: 238. DOI: 10.1016/j.jpag.2022.01.120.
- Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant UsersLazorwitz A, Pena M, Sheeder J, Teal S. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2022, 139: 579-587. PMID: 35594123, PMCID: PMC9140306, DOI: 10.1097/aog.0000000000004697.
- Concordance of Desired and Administered Postpartum Contraceptives among Emergency and Full Scope Medicaid PatientsWilson C, Lazorwitz A, Hyer J, Guiahi M. Concordance of Desired and Administered Postpartum Contraceptives among Emergency and Full Scope Medicaid Patients. Women's Health Issues 2022, 32: 343-351. PMID: 35272884, DOI: 10.1016/j.whi.2022.01.008.
- Discontinuation of hormonal contraception due to changes in mood and decreases in sexual desire: the role of adverse childhood experiencesNovick AM, Johnson RL, Lazorwitz A, Belyavskaya A, Berkowitz L, Norton A, Sammel MD, Epperson CN. Discontinuation of hormonal contraception due to changes in mood and decreases in sexual desire: the role of adverse childhood experiences. The European Journal Of Contraception & Reproductive Health Care 2022, 27: 212-220. PMID: 35133231, PMCID: PMC9133050, DOI: 10.1080/13625187.2022.2030702.
- Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic periodLazorwitz A, Sheeder J, Teal S. Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period. Contraception 2021, 108: 65-68. PMID: 34973207, PMCID: PMC9011406, DOI: 10.1016/j.contraception.2021.12.008.
- POSTER ABSTRACTS P58 THE EFFECT OF TOPIRAMATE ON ETONOGESTREL CONCENTRATIONS IN CONTRACEPTIVE IMPLANT USERSLazorwitz A, Peña M, Sheeder J, Teal S. POSTER ABSTRACTS P58 THE EFFECT OF TOPIRAMATE ON ETONOGESTREL CONCENTRATIONS IN CONTRACEPTIVE IMPLANT USERS. Contraception 2021, 104: 465. DOI: 10.1016/j.contraception.2021.07.076.
- POSTER ABSTRACTS P75 DEMOGRAPHIC DIVERSITY IN CONTRACEPTIVE CLINICAL TRIALS CONDUCTED AT AN ACADEMIC MEDICAL CENTERPeña M, Montford N, Sheeder J, Lazorwitz A. POSTER ABSTRACTS P75 DEMOGRAPHIC DIVERSITY IN CONTRACEPTIVE CLINICAL TRIALS CONDUCTED AT AN ACADEMIC MEDICAL CENTER. Contraception 2021, 104: 469. DOI: 10.1016/j.contraception.2021.07.093.
- INTEREST FOR AN AT-HOME TESTING KIT PROVIDING PERSONALIZED CONTRACEPTIVE RECOMMENDATIONS AMONG REPRODUCTIVE-AGE FEMALESLazorwitz A, Carrasco E, Cecula P, Sheeder J. INTEREST FOR AN AT-HOME TESTING KIT PROVIDING PERSONALIZED CONTRACEPTIVE RECOMMENDATIONS AMONG REPRODUCTIVE-AGE FEMALES. Fertility And Sterility 2021, 116: e292. DOI: 10.1016/j.fertnstert.2021.07.784.
- Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipientsLew J, Sheeder J, Lazorwitz A. Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients. Contraception 2021, 104: 556-560. PMID: 34147509, PMCID: PMC8502202, DOI: 10.1016/j.contraception.2021.06.007.
- Applicability of ancestral genotyping in pharmacogenomic research with hormonal contraceptionLazorwitz A, Aquilante C, Shortt J, Sheeder J, Teal S, Gignoux C. Applicability of ancestral genotyping in pharmacogenomic research with hormonal contraception. Clinical And Translational Science 2021, 14: 1713-1718. PMID: 33650294, PMCID: PMC8504805, DOI: 10.1111/cts.13014.
- Using pharmacologic research to efficiently meet acute contraceptive needsLazorwitz A, Teal S. Using pharmacologic research to efficiently meet acute contraceptive needs. Fertility And Sterility 2021, 115: 903-904. PMID: 33832748, PMCID: PMC9136044, DOI: 10.1016/j.fertnstert.2021.02.027.
- An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant usersLazorwitz A, Sheeder J, Teal S. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users. The European Journal Of Contraception & Reproductive Health Care 2021, 26: 323-325. PMID: 33596152, PMCID: PMC8496990, DOI: 10.1080/13625187.2021.1887475.
- An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant usersLazorwitz A, Dindinger E, Harrison M, Aquilante C, Sheeder J, Teal S. An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users. Contraception 2020, 102: 180-185. PMID: 32407811, PMCID: PMC7483263, DOI: 10.1016/j.contraception.2020.05.002.
- A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant usersLazorwitz A, Seale R, Davis A, Guiahi M. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users. Contraception 2020, 102: 58-60. PMID: 32325076, PMCID: PMC7272275, DOI: 10.1016/j.contraception.2020.04.011.
- Satisfaction with medication abortion and marijuana use: A prospective cohort studyFang N, Guiahi M, Lazorwitz A. Satisfaction with medication abortion and marijuana use: A prospective cohort study. Contraception 2020, 102: 30-33. PMID: 32278684, DOI: 10.1016/j.contraception.2020.03.008.
- Letter to the Editor in Response to “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally”Lazorwitz A, Aquilante C, Sheeder J, Teal S. Letter to the Editor in Response to “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally”. Advances In Therapy 2019, 37: 963-964. PMID: 31875298, PMCID: PMC6995783, DOI: 10.1007/s12325-019-01195-y.
- Pre- and post-operative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospitalLazorwitz A, Dindinger E, Aguirre N, Sheeder J. Pre- and post-operative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospital. Journal Of Anesthesia 2019, 34: 294-297. PMID: 31865457, PMCID: PMC8496978, DOI: 10.1007/s00540-019-02725-2.
- Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users.Lazorwitz A, Aquilante C, Dindinger E, Harrison M, Sheeder J, Teal S. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users. Obstetrics And Gynecology 2019, 134: 807-813. PMID: 31503152, PMCID: PMC6768730, DOI: 10.1097/aog.0000000000003452.
- Influence of genetic variants on weight gain among etonogestrel contraceptive implant usersLazorwitz A, Dindinger E, Harrison M, Aquilante C, Sheeder J, Teal S. Influence of genetic variants on weight gain among etonogestrel contraceptive implant users. Fertility And Sterility 2019, 112: e9-e10. DOI: 10.1016/j.fertnstert.2019.07.161.
- Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant usersLazorwitz A, Aquilante C, Sheeder J, Guiahi M, Teal S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. Contraception 2019, 100: 37-41. PMID: 30980827, PMCID: PMC6589369, DOI: 10.1016/j.contraception.2019.03.045.
- Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.Lazorwitz A, Aquilante C, Oreschak K, Sheeder J, Guiahi M, Teal S. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2019, 133: 783-794. PMID: 30870275, PMCID: PMC6448146, DOI: 10.1097/aog.0000000000003189.
- Ongoing Etonogestrel Contraceptive Implant Use Throughout PregnancyLazorwitz A, Coleman-Minahan K, Teal S, Guiahi M. Ongoing Etonogestrel Contraceptive Implant Use Throughout Pregnancy. Journal Of Adolescent Health 2018, 63: 363-364. PMID: 30076014, DOI: 10.1016/j.jadohealth.2018.03.021.
- A case series of removal of nickel–titanium sterilization microinserts from the uterine cornua using laparoscopic electrocautery for salpingectomyLazorwitz A, Tocce K. A case series of removal of nickel–titanium sterilization microinserts from the uterine cornua using laparoscopic electrocautery for salpingectomy. Contraception 2017, 96: 96-98. PMID: 28606383, DOI: 10.1016/j.contraception.2017.06.002.
- The effect of carbamazepine on etonogestrel concentrations in contraceptive implant usersLazorwitz A, Davis A, Swartz M, Guiahi M. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. Contraception 2017, 95: 571-577. PMID: 28288788, DOI: 10.1016/j.contraception.2017.03.004.
- The effect of carbamazepine on etonogestrel concentrations among contraceptive implant usersLazorwitz A, Swartz M, Davis A, Guiahi M. The effect of carbamazepine on etonogestrel concentrations among contraceptive implant users. Contraception 2016, 94: 389. DOI: 10.1016/j.contraception.2016.07.029.
- Does the expectation or perception of noncontraceptive benefits lead to higher rates of short-acting reversible contraceptive continuation for adolescents and young adult women?Lazorwitz A, Sheeder J, Teal S, Guiahi M. Does the expectation or perception of noncontraceptive benefits lead to higher rates of short-acting reversible contraceptive continuation for adolescents and young adult women? Contraception 2015, 91: 380-385. PMID: 25684618, DOI: 10.1016/j.contraception.2015.02.003.
- Does the expectation or perception of noncontraceptive benefits lead to higher rates of contraceptive continuation for adolescents and young adult women?Lazorwitz A, Sheeder J, Teal S, Guiahi M. Does the expectation or perception of noncontraceptive benefits lead to higher rates of contraceptive continuation for adolescents and young adult women? Contraception 2014, 90: 319. DOI: 10.1016/j.contraception.2014.05.093.
- Emergency ContraceptionLazorwitz A, Guiahi M. Emergency Contraception. Topics In Obstetrics & Gynecology 2014, 34: 1-6. DOI: 10.1097/01.pgo.0000449926.51072.c3.
- Increasing Use of and Adherence to Long-Acting Reversible Contraceptive Methods in Adolescents and Young Adult WomenLazorwitz A, Guiahi M. Increasing Use of and Adherence to Long-Acting Reversible Contraceptive Methods in Adolescents and Young Adult Women. Topics In Obstetrics & Gynecology 2014, 34: 1-7. DOI: 10.1097/01.pgo.0000442955.12502.a3.
- Identification of Breast Cancer DNA Methylation Markers Optimized for Fine-Needle Aspiration SamplesBu D, Lewis C, Sarode V, Chen M, Ma X, Lazorwitz A, Rao R, Leitch M, Moldrem A, Andrews V, Gazdar A, Euhus D. Identification of Breast Cancer DNA Methylation Markers Optimized for Fine-Needle Aspiration Samples. Cancer Epidemiology Biomarkers & Prevention 2013, 22: 2212-2221. PMID: 24089458, DOI: 10.1158/1055-9965.epi-13-0208.
- Abstract 4934: Promoter methylation biomarkers for breast cancer risk stratification using an unbiased whole genome approachLewis C, Bu D, Lazorwitz A, Leonard D, Euhus D. Abstract 4934: Promoter methylation biomarkers for breast cancer risk stratification using an unbiased whole genome approach. Cancer Research 2010, 70: 4934-4934. DOI: 10.1158/1538-7445.am10-4934.